市場調査レポート
商品コード
1462259
INBRIJA市場:市場規模、予測、市場洞察-2032年INBRIJA Market Size, Forecast, and Market Insight - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
INBRIJA市場:市場規模、予測、市場洞察-2032年 |
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
INBRIJAは、レボドパの乾燥粉末製剤で、インブリジャ吸入器による経口吸入用です。吸入用粉末は白色のヒプロメロースカプセルに包装されています。各カプセルにはレボドパ有効成分42mgの噴霧乾燥粉末と1、2-ジパルミトイル-sn-グリセロ-3-ホスホコリン(DPPC)および塩化ナトリウムが含まれています。
INBRIJAの有効成分は、芳香族アミノ酸であるレボドパです。化学名は(2S)-2-アミノ-3-(3,4-ジヒドロキシフェニル)プロパン酸で、分子量は197.19g/mol、分子式はC9H11NO4です。
今後数年間で、パーキンソン病の市場シナリオは、世界中の広範な調査と医療費の増加により変化します。
各社は、病状を治療/改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、インブリジャの優位性に影響を与える可能性のある機会を模索しています。
パーキンソン病治療薬の他の新興製品も、INBRIJAと厳しい市場競争を繰り広げることが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。
当レポートでは、主要7ヶ国におけるパーキンソン病治療薬のINBRIJA市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。
"INBRIJA Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about INBRIJA for Parkinson's disease in the seven major markets. A detailed picture of the INBRIJA for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the INBRIJA for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the INBRIJA market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.
INBRIJA consists of a dry powder formulation of levodopa for oral inhalation with the INBRIJA inhaler. The inhalation powder is packaged in white hypromellose capsules. Each capsule contains a spray-dried powder of 42 mg levodopa active ingredient with 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and sodium chloride.
The active component of INBRIJA is levodopa, an aromatic amino acid. Its chemical name is (2S)-2-amino-3-(3,4-dihydroxyphenyl) propanoic acid and its molecular weight is 197.19 g/mol and the molecular formula is C9H11NO4.
Dosage and administration
INBRIJA consists of a dry powder formulation of levodopa for oral inhalation with the INBRIJA inhaler. The therapeutic capsule contains 42 mg levodopa for use in an INBRIJA inhaler. The INBRIJA inhaler is a plastic device with a blue body, blue cap, and white mouthpiece used for inhaling INBRIJA powder. INBRIJA capsules are needed up to 5 times daily. The maximum recommended daily dosage of INBRIJA is 420 mg.
Mechanism of action
Levodopa, the metabolic precursor of dopamine, crosses the blood-brain barrier and presumably is converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa relieves symptoms of Parkinson's disease.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
INBRIJA Analytical Perspective by DelveInsight
This report provides a detailed market assessment of INBRIJA for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
The report provides the clinical trials information of INBRIJA for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.